Basic Information
| LncRNA/CircRNA Name | LINC00052 |
| Synonyms | LINC00052, NCRNA00052, TMEM83 |
| Region | GRCh38_15:87576929-87579866 |
| Ensemble | ENSG00000259527 |
| Refseq | NR_026869 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, RIP etc. |
| Sample | hepatocellular carcinoma tissues, cell lines (L02, SMMC7721, SK-hep1, Huh7, HepG2) |
| Expression Pattern | up-regulated |
| Function Description | We found that overexpression of LINC00052 could upregulate the EPB41L3 expression and it might serve as a tumor suppressor gene in HCC. Database analysis showed that miR-452-5P could target LINC00052. The binding regions between LINC00052 and miR-452-5P were confirmed by luciferase assays. Moreover, LINC00052 inhibited cell malignant behavior by increasing miR-452-5P expression, suggesting that LINC00052 was negatively regulated by miR-452-5P.In addition, overexpression of miR-452-5P resulted in a decrease of EPB41L3 expression, suggesting that EPB41L3 was as a target of miR-452-5P. In conclusion, these results demonstrated that a novel pathway was mediated by LINC00052 in HCC. |
| Pubmed ID | 28969024 |
| Year | 2017 |
| Title | LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p. |
External Links
| Links for LINC00052 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |